



CalRx® Insulin Patient Advisory Council Kickoff  
Insulin Market Discussion Questions  
Tuesday, April 29, 2025

**1. Ensuring Equitable Insulin Access & Affordability**

- a. What is top of mind for you in ensuring equitable access to insulin?
- b. What is top of mind for you regarding insulin affordability?
- c. What other challenges do consumers face regarding insulin availability and managing their treatment regimen?

**2. Biosimilar vs. Brand Insulin Preference**

We would like to better understand the potential barriers to accessing more affordable, FDA-approved biosimilar insulins, such as formulary coverage by pharmacy benefit managers (PBMs) and consumer concerns about efficacy.

- a. What are the key barriers to uptake of biosimilar insulins?
- b. How do consumers perceive the effectiveness of biosimilar insulins?
- c. Are there patient education models, frameworks, or resources that you've found useful in alleviating consumer concerns about biosimilar insulins?
- d. What do insured patients experience when their health plan changes the formulary, and their current insulin is now listed as "not covered"?

**3. Mail Order vs. Community Pharmacy Preference**

We would like to better understand the potential barriers to accessing community pharmacies and utilizing mail-order pharmacies, such as the logistics of cold-chain transport and the need for insulin to be temperature controlled at the point of delivery (i.e., not sitting out for excessive periods).

- a. How does the location or convenience of community pharmacies impact consumer access to insulin?
- b. How do consumers perceive the use of mail-order pharmacies for accessing insulin?
- c. What are the key barriers to uptake of mail-order pharmacies for accessing insulin?



**4. Feedback on Existing Insulin Discount & Access Programs**

We would like to better understand the potential barriers to participating in insulin discount and access programs, such as discount cards or copay programs.

- a. What do consumers experience when navigating participation in these programs?
- b. For those of you that work in advocacy, how are insulin manufacturers responding to concerns about barriers to accessing these programs?
- c. How do consumers perceive the use of direct-to-consumer models being offered by insulin manufacturers (e.g., Lilly Direct)?